Health Robotics, a manufacturer of intravenous medication robots will unveil its new cancer therapy robot at the European Association of Hospital Pharmacists (EAHP) in Vienna on 1 April 2011. The company stated that it had completed initial research, development and factory testing of its next-generation robot, i.v.STATION ONCO.

This robot includes new overpowering features: it's four times faster, five times smaller, and three times less expensive than some of the other Sterile Compounding Robotic devices in the market.

“i.v.STATION ONCO symbolizes the next pillar in Health Robotics' strategy to build a cost-effective, redundant, and patient-safe network of devices that address the flexibility, throughput, high-availability, and protection required within Cancer Therapy," stated Gaspar DeViedma, Health Robotics' executive vice president.

The robot is scheduled be released to Beta-Test and Early Adopter Program status in approximately 6 months to Generale de Sante in Paris, Bolzano General Hospital in Italy, working with CytoCare and Health Robotics's South  East Asia's own compounding center in Kuala Lumpur, Malaysia.

"I do believe that it is now the right time for Generale de Sante to move forward to Robotics Automation for our strategic Oncology Sterile Compounding workflow processes," said Filippo Monteleone, Generale de Sante's managing director.

Dr. Pietro Paluselli, Director of Pharmacy at Bolzano General Hospital added, "We look forward to repeat the rigorous SafeChemo scientific validation we undertook with CytoCare in 2008, including world-leading and peer-reviewed sterility and cross-contamination tests with i.v.STATION ONCO, and to divide our Oncology Therapy workload with CytoCare, each robot being utilized for a particular purpose and need."

Health Robotics is actively marketing this technology in different parts of the world, including an agreement with Charite-Universitatsmedizin, Berlin and with Devon International to offer robotic technology in China.

In September 2010, the company stated that it had signed five exclusive distribution agreements for their CytoCare, i.v.STATION, and i.v.SOFT technologies in four Eastern European countries.